Lehners, M., Dobrowinski, H., Feil, S
Key Characteristics of LGlutathione Tripeptide Structure: Made of glutamate, cysteine, and glycine, with a -bond that helps resist rapid breakdown by common peptidases
AOD-9604 FDA Approval History At a glance FDA approval status / Never approved for any indication in the United States NDA filing history / No New Drug Application has ever been submitted to FDA Chemical identity / Synthetic peptide corresponding to amino acids 176-191 of human growth hormone, with a tyrosine residue added at the C-terminus Developer / Metabolic Pharmaceuticals Ltd (Melbourne, Australia), now defunct Clinical trial outcome / Phase IIb trial (2007) failed to meet primary efficacy endpoint for obesity FDA compounding status / Placed on Category 2 list
Ideal for studies focusing on tissue repair, accelerated recovery, and anti-inflammatory effects, this peptide blend presents a forefront opportunity in regenerative medicine research
Whether KL1 directly binds to and inhibits EHMT2/G9a remains to be determined
Differential Effect of Serotonin on Cytokine Production in Lipopolysaccharide-Stimulated Human Peripheral Blood Mononuclear Cells: Involvement of 5-hydroxytryptamine2A Receptors
